Placebo product for INP20 clinical trials

A multicenter double-blind, randomized, placebo-controlled phase I/II study to determine the safety, tolerability, potential efficacy and dose finding of INP20, an oral formulation for treatment of immunotherapy in peanut-allergic patients.

This study is testing a new oral medication, INP20, for people with peanut allergies. It aims to see if it's safe, how well people tolerate it, to find the right dose, and if it helps reduce allergic reactions to peanuts.